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SUMMARY
An abnormal cellobiose/mannitol ratio is present in new patients presenting
with dermatitis herpetiformis and in patients who have never adhered to a strict
gluten-free diet. In patients with dermatitis herpetiformis in remission on a strict
gluten-free diet, smallbowelabsorption as measuredby thecellobiose/mannitol
ratio is normal. It is suggested that cellobiose/mannitol ratio absorption is a
useful screening test for the intestinal abnormality associated with dermatitis
herpetiformis andfailure ofthe test to return to normal couldsuggestpoordietary
compliance.
INTRODUCTION
Dermatitis herpetiformis was shown to be associated with jejunal villous atrophy
by Marks et all and changes similar to those in coeliac disease have been
found.23 Although between one-third and one-fifth of dermatitis herpetiformis
patients do not demonstrate jejunal villous changes,3-5 most patients show an
improvement on a gluten -free diet. Tests ofabsorption tend to be normal or only
slightly abnormal.5-7 The mucosal changes are said to be patchy,8 so that simple
screening tests have not been found useful in assessing mucosal recovery and
repeated jejunal biopsies may not give accurate information. A reproducible
absorption test would be invaluable in the clinical management of these patients,
as it would appear that clinical remission occurs only after the mucosa has
returned to normal.9 10
Abnormal sugar absorption has been shown to be a useful measure for screening
jejunal function in patients with coeliac disease.1 12 Cellobiose/mannitol absorp-
tion has been well studied with reports of clear separation between active coeliac
disease and coeliac disease in remission.13 We felt that cellobiose/mannitol
absorption might be a useful test in patients with dermatitis herpetiformis.
Abnormal persistent defects in permeability have been demonstrated in coeliac
disease and dermatitis herpetiformis patients, even if the disease is in remission
and the mucosa has returned to normal using the 51 chromium -labelled
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ethylene-diamine tetra-acetate (51 Cr/EDTA) absorption test.)4 However, in the
clinical management of patients, a simple demonstration of recovery of
absorptive ability is all that is required.
The present study comprises a group of patients with dermatitis herpetiformis
who have been followed up for a number of years, and five patients, newly
diagnosed, who have not yet started on the gluten-free diet. We measured the
cellobiose/mannitol ratio, assessed the clinical response to a gluten-free diet,
and looked for a correlation between the original jejunal biopsy and clinical
response.
MATERIALS AND METHODS
A total of 20 patients with dermatitis herpetiformis was investigated of whom five
were newly diagnosed cases (two men and three women; mean age 42 years;
range 23-62 years) taking a normal diet. The remaining 15 patients (10 men
and 5 women of mean age 45 years; range 19 - 78 years) had been on gluten -
free diet treatment for a mean of eight years (range 1 - 13 years) at the time ofthe
study. A jejunal biopsy had been taken before the start of gluten restriction. The
diagnosis of dermatitis herpetiformis was based on the characteristic body
distribution of an intensely pruritic, polymorphic and vesicular skin rash together
with the demonstration by immunofluorescence of IgA deposits in the papillary
dermis of clinically uninvolved skin.)5 16 In a few patients presenting before the
availability of IgA immunofluorescence, a classical skin rash associated with
abnormal histology and a clinical response to dapsone was accepted as diagnostic
of dermatitis herpetiformis.
Biopsy of the upper jejunal mucosa was carried out using a Watson capsule
placed endoscopically in the second part of the duodenum and the capsule then
advanced 25cm distally from the end of the endoscope. The mucosa was
examined under the dissecting microscope, following which routine microscopic
sections were stained with haematoxylin and eosin. The biopsies were graded
as normal, partial villous atrophy and subtotal villous atrophy. Increased intra -
epithelial lymphocytic infiltration in the presence of otherwise normal villi has
been accepted as partial villous atrophy.
Cellobiose/mannitol absorption
A sugar solution composed of 2gm mannitol, 5gm cellobiose, 20gm lactose,
20gm sucrose, made up to 150ml was the test solution. After an overnight fast,
the patient emptied his bladder and drank the solution over a period of five
minutes. All urine passed within the next five hours was collected. The amount of
mannitol and cellobiose passed in the urine was measured as outlined by Strobel
et al.)3 The results were expressed in percentages and the final ratio of percentage
recovery of cellobiose to percentage recovery of mannitol was calculated as the
cellobiose/mannitol ratio. A cellobiose/mannitol ratio of less than 0.037 was
accepted as normal.
RESULTS
The cellobiose/mannitol ratio in the five untreated dermatitis herpetiformis
patients was at or above the normal range (0.037-0.19). The remaining 15
patients had been diagnosed one to 13 years previously, and cellobiose/mannitol
ratio varied from 0.001 -0.22 (Table 1).
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TABLE I
Dermatitis herpetiformis: cellobiose/mannitol ratio (normal < 0.037) in five
newly diagnosed (untreated), and 15 previously diagnosed patients
Newly diagnosed
0.037*
0.190*
0.064*
0.110*
0.047
*
Gluten-free diet
0.024
0.006
0.005
0.002
0.010
0.023
0.031
0.047
*
Stopped diet
0.001
0.019
0.014
Never on
gluten restriction
0.220*
0.064*
0.011
0.039*
*Abnormal result.
Seven of the previously treated patients had no skin symptoms and a normal
cellobiose/mannitol ratio: six were on a gluten-free diet, but one who had been
on a diet for a number of years had found it inconvenient and continued on
dapsone (Table II). Eight previously treated patients had persistent or intermittent
blistering and itch of the skin. Two had been on a strict gluten -free diet for seven
years, but had stopped, and they had a normal cellobiose/mannitol ratio at the
time of study. Two patients continued on a strict gluten -free diet one of these
had a normal ratio and the other who had been on a gluten-free diet for only two
months, with noticeable improvement of the skin, had an abnormal ratio. Four of
these 15 patients had never been on a gluten-free diet and had persisting skin
problems; three of these had an abnormal ratio.
TABLE II
Skin response and cellobiose/mannitol ratio
Cellobiose/mannitol ratio
Complete remission Active skin disease
0.024 0.019
0.006 0.014
0.005 0.031
0.002 0.047*
0.010 t 0.220*
0.023 t 0.064*
tO0.001 tO.011
0.039*
*Abnormal results.
t Patients on dapsone.
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Thus, of nine patients (five new, four previously treated) not on a gluten-free diet
at the time of study, eight had an abnormal cellobiose/mannitol ratio, and of 11
patients who had been or were on a strict gluten -free diet, 10 had a normal ratio.
The one patient with an abnormal ratio had been on a diet for only two months.
The initial jejunal biopsy was reported as showing partial villous atrophy in all five
newly diagnosed patients who were on a normal diet and in seven of the 15
previously diagnosed patients. Four of the old patients had sub-total villous
atrophy and the remaining four had a normal or minimal change mucosa.
Subsequent response to a gluten-free diet did not depend on the initial biopsy.
Eleven patients had used dapsone 100mg daily with relief of symptoms at the
onset of the disease. Three patients with poor dietary compliance continued to
use it intermittently with some benefit and two out of three have an abnormal
cellobiose/mannitol ratio. One patient who had been well controlled on diet has a
normal ratio and continues to use dapsone, as he finds it more convenient than a
strict gluten-free diet.
DISCUSSION
This study indicates a possible clinical use for the measurement ofthe cellobiose/
mannitol ratio. The abnormal ratio in new untreated patients could be used as a
screening test either prior to or instead of a jejunal biopsy. There is very good
separation between patients well controlled on a gluten -free diet and new
patients. Repeated tests of patients who are on a gluten-free diet could measure
both dietary compliance and an improvement in jejunal mucosa. Poor dietary
compliance appears to be linked to poor control ofthe skin condition.9 The actual
defect in dermatitis herpetiformis is not clear but there is evidence to suggest that
an abnormal leaky jejunal mucosa leads to an absorption of immune complexes
which, deposited in the skin, can lead to intense pruritis.17 18
Published results tend to beconfusing aboutthe benefitofa gluten-free diet.9 19,20
In this study, however, it would appear that strict gluten exclusion leads to good
control of dermatitis herpetiformis. The speed of response varies in that the rash
responds rapidly to gluten exclusion in some patients, perhaps within a few
weeks, while in other patients a gluten-free diet is necessary for many months
before remission is obtained.
Ifjejunal 'healing' is necessary for a remission of dermatitis herpetiformis it would
be interesting to follow up a group of patients with dermatitis herpetiformis taking
serial measurements of the cellobiose/mannitol ratio to see if permeability has to
return to normal before skin remission occurs. Our preliminary results suggest
that cellobiose/mannitol absorption studies may be a good measure of jejunal
healing and presumably of dietary compliance. Further investigation is necessary
to find if skin improvement occurs at the same time as, or subsequent to jejunal
recovery.
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